Health Topics — Metabolic & Cognitive
Weight That Won't Move — and Why Stress Might Be the Reason
For the person who is eating carefully, moving regularly, and still not seeing results — what the research shows about cortisol, visceral fat, and the endocannabinoid system.
You have been doing the things you're supposed to do. Eating carefully. Moving regularly. And yet the weight — particularly around your middle — doesn't shift the way it used to, or the way the effort seems to warrant. It is one of the more frustrating experiences in health: doing everything right and getting results that don't match the effort.
There is a biological explanation that has nothing to do with discipline or consistency. It involves cortisol, and it is worth understanding.
Cortisol drives visceral fat accumulation. This is not a metaphor for stress making people eat more — though that is also real. It is a direct hormonal mechanism. Visceral adipose tissue — the fat that accumulates around the internal organs, in the abdominal area — has a high density of cortisol receptors. Under chronically elevated cortisol, these receptors respond by promoting fat storage specifically in this tissue. The body, under sustained stress, is biologically inclined to store fat in the place where it has the most cortisol-responsive cells.
Cortisol also promotes insulin resistance — a state in which cells become less responsive to insulin's signal to absorb glucose from the blood. When cells resist insulin, blood glucose stays elevated, more insulin is produced in response, and more glucose is converted to fat for storage. This cascade — cortisol to insulin resistance to fat accumulation — is a documented metabolic pathway, not a theory. It explains why people under chronic stress can gain weight or fail to lose it even when their caloric intake and expenditure seem to be managed correctly.
The endocannabinoid system's role in metabolic regulation
The endocannabinoid system is present in the metabolic tissues that govern fat storage and energy regulation — including adipose tissue, the liver, and the hypothalamus. CB1 receptors in these tissues play a documented role in regulating appetite signals, fat storage patterns, and insulin sensitivity. This is not a minor or peripheral role. The ECS is part of the metabolic regulatory architecture.
The most striking evidence of this comes from an unlikely source: a pharmaceutical drug called rimonabant, developed as a CB1 receptor blocker for obesity, which was withdrawn from the market in 2008 due to severe psychiatric side effects. Its metabolic effects were real — blocking CB1 in metabolic tissue produced measurable reductions in visceral fat and improvements in metabolic markers. The withdrawal was not because the metabolic mechanism was wrong. It was because globally blocking CB1 in the brain produced intolerable consequences. What rimonabant established is the architecture: the ECS in metabolic tissue is a real and meaningful regulatory system.
Under chronic stress, CB1 receptor activity in hypothalamic appetite circuits is increased by elevated endocannabinoid tone — a pattern that promotes appetite for energy-dense food. The same chronic stress depletes endocannabinoid tone in stress-regulatory circuits, as described in other articles. These are different tissue populations responding differently to the same systemic stress signal. The result, in metabolic terms, is an appetite that is up-regulated at the same time that the body's ability to resolve the stress driving it is down-regulated.
What the research on CBG and CBD connects to here
Neither CBG nor CBD has been studied for weight loss or visceral fat reduction in human trials. We do not suggest that they would produce these outcomes, and we do not present the mechanistic research as equivalent to clinical evidence of effect.
What the research does establish is the upstream connection: CBG's documented stress-reducing effect in the Cuttler trial — reducing perceived stress and anxiety following a single oral dose — is relevant to a metabolic pattern that is driven upstream by chronic stress and cortisol. A preparation that genuinely supports the body's stress response may, over time, reduce the cortisol burden that promotes visceral fat accumulation. This is a plausible biological pathway, not an established finding.
CBG's PPAR-γ agonist activity — documented in colonic tissue research — is also relevant. PPAR-γ receptors in adipose and metabolic tissue play a role in insulin sensitivity and fat cell differentiation. The same receptor targeted by a class of pharmaceutical diabetes medications. CBG's activity here is preclinical and indirect — but the pathway is real.
On weight, compliance, and honest framing
Weight management claims are among the most heavily scrutinized in the regulatory landscape. We make none. The research described here is mechanistic and contextual — it documents biological pathways, not weight outcomes.
If the cortisol-metabolism pattern described here resonates with your experience, it is worth discussing with a clinician who can assess your hormonal and metabolic picture directly.
What this means in practice
The most useful thing this article can offer is a framework: if you are doing everything that conventional weight management advice recommends and not seeing results, chronic cortisol and its metabolic consequences are worth understanding as a possible underlying factor. Addressing the stress load — not just the dietary and exercise pattern — may be as relevant to the metabolic picture as anything else you are doing.
Future articles in this pillar examine the ECS and metabolic regulation in deeper detail, the glucose regulation research, and the energy balance mechanisms the ECS is involved in. The research section is the place to start if you want the fuller picture now.
Weight that won't move despite effort is not a failure of discipline. It may be a metabolic pattern shaped by cortisol, insulin resistance, and the endocannabinoid system's role in fat storage and appetite regulation — a biology that diet and exercise alone may not be sufficient to address. The research on CBG and the stress response is relevant to this picture through the upstream cortisol pathway. We present it in that proportion — as context, not as a weight management claim.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.